Logo

OxMol Collaborates With Mitsubishi on Discovery

Dec 18, 1998
Premium

CAMPBELL, Calif.--The collaborative discovery division of Oxford Molecular Group, in a contract with Cambridge Combinatorial, announced that it will undertake a research program in drug discovery with Mitsubishi Chemical. The program aims to identify novel lead compounds for the treatment of metabolic disorders and utilizes the molecular design, medicinal chemistry, and combinatorial chemistry expertise of both companies. Mitsubishi will pay Oxford and Cambridge an undisclosed upfront payment, ongoing research fees, research milestones, and success payments in the drug development process, in addition to royalties on any compounds that are commercialized. Oxford also announced that it has invested £2.5 million in MicroGenics, a new company that will develop screening systems for novel antimicrobials.

Filed under

Informatics
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.